# P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

> **NCT02533323** · PHASE2 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 50 (actual)

## Conditions studied

- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** oxaliplatin
- **DRUG:** pegaspargase

## Key facts

- **NCT ID:** NCT02533323
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2016-09
- **Final completion:** 2017-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533323, "P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02533323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*